FBXL19-AS1
gene geneOn this page
Also known as MGC125469MGC125470MGC125472
Summary
FBXL19-AS1 (FBXL19 antisense RNA 1, HGNC:27557) is a long non-coding RNA gene on chromosome 16p11.2.
At a glance
- Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:27557 |
| Approved symbol | FBXL19-AS1 |
| Name | FBXL19 antisense RNA 1 |
| Location | 16p11.2 |
| Locus type | RNA, long non-coding |
| Status | Approved |
| Aliases | MGC125469, MGC125470, MGC125472 |
| Ensembl gene | ENSG00000260852 |
| Ensembl biotype | lncRNA |
| Entrez | 283932 |
| RNAcentral | URS00002206F5 — lncRNA, 3951 nt, 1 organism(s) |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 lncRNA
ENST00000563777
RefSeq mRNA: 0 — MANE Select: None
Canonical transcript exons
ENST00000563777 — 1 exons
| Exon | Start | End |
|---|---|---|
| ENSE00004182563 | 30919319 | 30923279 |
Expression profiles
Bgee: expression breadth ubiquitous, 152 present calls, max score 69.67.
FANTOM5 (CAGE): breadth broad, TPM avg 1.0690 / max 29.3620, expressed in 607 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 157104 | 1.0690 | 607 |
Top tissues by expression
242 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| ganglionic eminence | UBERON:0004023 | 69.67 | gold quality |
| ventricular zone | UBERON:0003053 | 66.92 | gold quality |
| stromal cell of endometrium | CL:0002255 | 66.53 | gold quality |
| islet of Langerhans | UBERON:0000006 | 66.50 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 66.25 | gold quality |
| spinal cord | UBERON:0002240 | 63.89 | gold quality |
| endothelial cell | CL:0000115 | 63.15 | gold quality |
| sural nerve | UBERON:0015488 | 63.01 | silver quality |
| rectum | UBERON:0001052 | 62.73 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 62.37 | gold quality |
| right adrenal gland | UBERON:0001233 | 62.03 | gold quality |
| cortical plate | UBERON:0005343 | 61.78 | gold quality |
| vermiform appendix | UBERON:0001154 | 61.65 | gold quality |
| granulocyte | CL:0000094 | 61.52 | gold quality |
| left adrenal gland | UBERON:0001234 | 61.40 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 61.09 | gold quality |
| apex of heart | UBERON:0002098 | 60.75 | gold quality |
| monocyte | CL:0000576 | 60.40 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 60.38 | gold quality |
| leukocyte | CL:0000738 | 60.36 | gold quality |
| adrenal gland | UBERON:0002369 | 59.85 | gold quality |
| myocardium | UBERON:0002349 | 59.73 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 59.61 | gold quality |
| adrenal cortex | UBERON:0001235 | 59.36 | gold quality |
| body of stomach | UBERON:0001161 | 59.03 | gold quality |
| prefrontal cortex | UBERON:0000451 | 58.75 | gold quality |
| transverse colon | UBERON:0001157 | 58.62 | gold quality |
| superficial temporal artery | UBERON:0001614 | 58.47 | gold quality |
| gall bladder | UBERON:0002110 | 58.25 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 58.13 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 2.30 |
Regulation
Is transcription factor: no
Literature-anchored findings (GeneRIF, showing 10)
- results reveal the cancer-promoting effect of FBXL19-AS1, acting as a molecular sponge in negatively modulating miR-203, which might provide a new insight for understanding of colorectal cancer development (PMID:28479250)
- these results indicated that FBXL19-AS1 was involved in progression and angiogenesis in lung cancer by targeting miR-431-5p/RAF1 axis, which provided a new insight into the therapeutic strategies of lung cancer. (PMID:30610161)
- FBXL19-AS1 expression and role in cell migration, invasion, and epithelial-mesenchymal transition in breast cancer.LIN28A-stabilized FBXL19-AS1. (PMID:31140103)
- Long noncoding RNA FBXL19-AS1 induces tumor growth and metastasis by sponging miR-203a-3p in lung adenocarcinoma. (PMID:31566718)
- This study revealed the regulatory mechanism of FBXL19-AS1 in breast cancer and suggested a comprehensive and feasible FBXL19-AS1-mediated therapeutic approach for treating breast cancer. (PMID:31696201)
- IGF2BP2 stabilized FBXL19-AS1 regulates the blood-tumour barrier permeability by negatively regulating ZNF765 by STAU1-mediated mRNA decay. (PMID:32713259)
- LncRNA FBXL19-AS1 promotes the development of gastric cancer by regulating miR-876-5p/ HMGB3 axis. (PMID:32883406)
- Long non-coding RNA FBXL19-AS1 serves as a competing endogenous RNA to regulate ZEB1 expression by sponging miR-431 in gastric cancer. (PMID:33168132)
- Analysis of associations of FBXL19-AS1 with occurrence, development and prognosis of acute pancreatitis. (PMID:33378025)
- Exploring the regulatory role of FBXL19-AS1 in triple-negative breast cancer through the miR-378a-3p/OTUB2 axis. (PMID:38702967)
Cross-species orthologs
0 orthologs
Protein
Non-coding RNA — no protein product; not a drug target.
Function
No curated pathway, Gene-Ontology, or interaction data.
Disease & clinical
No curated disease, variant, or cancer-driver associations.
Drugs & pharmacology
No drug or pharmacology data — not an established drug target.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.